Post-acute blood biomarkers and disease progression in traumatic brain injury

Virginia F J Newcombe, Nicholas J Ashton, Jussi P Posti, Ben Glocker, Anne Manktelow, Doris A Chatfield, Stefan Winzeck, Edward Needham, Marta M Correia, Guy B Williams, Joel Simrén, Riikka S K Takala, Ari J Katila, Henna Riikka Maanpää, Jussi Tallus, Janek Frantzén, Kaj Blennow, Olli Tenovuo, Henrik Zetterberg, David K Menon, Virginia F J Newcombe, Nicholas J Ashton, Jussi P Posti, Ben Glocker, Anne Manktelow, Doris A Chatfield, Stefan Winzeck, Edward Needham, Marta M Correia, Guy B Williams, Joel Simrén, Riikka S K Takala, Ari J Katila, Henna Riikka Maanpää, Jussi Tallus, Janek Frantzén, Kaj Blennow, Olli Tenovuo, Henrik Zetterberg, David K Menon

Abstract

There is substantial interest in the potential for traumatic brain injury to result in progressive neurological deterioration. While blood biomarkers such as glial fibrillary acid protein (GFAP) and neurofilament light have been widely explored in characterizing acute traumatic brain injury (TBI), their use in the chronic phase is limited. Given increasing evidence that these proteins may be markers of ongoing neurodegeneration in a range of diseases, we examined their relationship to imaging changes and functional outcome in the months to years following TBI. Two-hundred and three patients were recruited in two separate cohorts; 6 months post-injury (n = 165); and >5 years post-injury (n = 38; 12 of whom also provided data ∼8 months post-TBI). Subjects underwent blood biomarker sampling (n = 199) and MRI (n = 172; including diffusion tensor imaging). Data from patient cohorts were compared to 59 healthy volunteers and 21 non-brain injury trauma controls. Mean diffusivity and fractional anisotropy were calculated in cortical grey matter, deep grey matter and whole brain white matter. Accelerated brain ageing was calculated at a whole brain level as the predicted age difference defined using T1-weighted images, and at a voxel-based level as the annualized Jacobian determinants in white matter and grey matter, referenced to a population of 652 healthy control subjects. Serum neurofilament light concentrations were elevated in the early chronic phase. While GFAP values were within the normal range at ∼8 months, many patients showed a secondary and temporally distinct elevations up to >5 years after injury. Biomarker elevation at 6 months was significantly related to metrics of microstructural injury on diffusion tensor imaging. Biomarker levels at ∼8 months predicted white matter volume loss at >5 years, and annualized brain volume loss between ∼8 months and 5 years. Patients who worsened functionally between ∼8 months and >5 years showed higher than predicted brain age and elevated neurofilament light levels. GFAP and neurofilament light levels can remain elevated months to years after TBI, and show distinct temporal profiles. These elevations correlate closely with microstructural injury in both grey and white matter on contemporaneous quantitative diffusion tensor imaging. Neurofilament light elevations at ∼8 months may predict ongoing white matter and brain volume loss over >5 years of follow-up. If confirmed, these findings suggest that blood biomarker levels at late time points could be used to identify TBI survivors who are at high risk of progressive neurological damage.

Keywords: glial fibrillary acid protein (GFAP); neurofilament light (NFL); neuroimaging; outcome; traumatic brain injury.

© The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain.

Figures

Figure 1
Figure 1
Comparison of healthy volunteer levels of GFAP (A) and NFL (B) (plotted on a linear scale) compared to patients approximately 8 months and >5 years after a TBI. GFAP: healthy volunteer (HV) versus TBI ∼8 monthsP = 0.086, HV versus TBI >5 years P = 0.11, TBI ∼8 months versus TBI >5 years P = 0.0087. NFL: HV versus TBI ∼6months P < 0.0001, HV versus TBI >5 yearsP = 0.55, TBI ∼8 months versus TBI >5 yearsP = 0.0025. ns P > 0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.
Figure 2
Figure 2
Log GFAP and log NFL levels correlate at each time point post-TBI (A: ~6 to 8 months; and B: >5 years after injury), but the strength of this correlation decreases over time. The R2 are shown adjusted for age, sex, and time since injury. GFAP and NFL are shown on log scales, but figures denote actual concentrations in pg/ml.
Figure 3
Figure 3
Temporal changes in GFAP (A) and NFL (B) in patient subset with data at ∼8 months and >5 years post-TBI (absolute values). The solid horizontal line represents the mean value for healthy volunteers and the dotted lines the standard deviations.
Figure 4
Figure 4
Log GFAP and log NFL levels at ∼8 months significantly correlate with fractional anisotropy and mean diffusivity in WBWM (A, B, E and F), mean diffusivity in the cortical grey matter (C and G) and the deep grey matter (D and H). TheR2 values shown are adjusted for age, sex, and time since injury. GFAP and NFL are shown on log scales, but figures denote actual concentrations in pg/ml.
Figure 5
Figure 5
Predicted brain age, predicted brain age difference for patients imaged >5 years after injury, and the mean JD for the subset of patients and controls imaged longitudinally. Predicted brain age versus actual for grey matter (WBGM) (A: Healthy volunteers R = 0.85 P < 0.0001, Patients R = 0.83, P < 0.0001) and WBWM (B: Healthy Volunteers 0.77, P < 0.001, Patients R = 0.87P < 0.001). Comparison of PAD and mean JD for WBGM and WBWM between healthy volunteers and patients >5 years after injury (C andD). Comparison of the mean JD for WBGM and WBWM between patients imaged from ∼8 months and >5 years after injury compared to controls imaged twice over the same period (E and F). ****P < 0.00001.
Figure 6
Figure 6
Grey (A) and white matter (B) VBM for patients >5 years after TBI and control subjects. Results are corrected for FWE P < 0.05. The covariates in the model were age, sex and total intracranial volume.
Figure 7
Figure 7
NFL levels at ∼8 months post-TBI, adjusted for age, sex, and time post-TBI, predict WBWM rate of volume loss between ∼8 months and >5 years defined using the JD. Adjusted R = 0.41, P = 0.04. Absolute values for NFL shown (pg/ml).
Figure 8
Figure 8
PAD and biomarker levels at 5-year MRI in patient subgroups.(A and B) PAD in WBGM and WBWM and (C andD) levels of GFAP and NFL at >5-year MRI in subgroups of patients who showed improving (Improve; increase in GOSE ≥ 1 point), stable (no change in GOSE), or worsening (Worse; reduction in GOSE ≥ 1 point) between ∼8 months and >5 years post-injury. HV = healthy volunteers. Figures above box plots show unadjustedP-values for comparisons (Mann-Whitney U).

References

    1. Czeiter E, Amrein K, Gravesteijn BY, et al. . Blood biomarkers on admission in acute traumatic brain injury: Relations to severity, CT findings and care path in the CENTER-TBI study. EBioMedicine. 2020;56:102785.
    1. Maas AIR, Menon DK, Adelson PD, et al. . Traumatic brain injury: Integrated approaches to improve prevention, clinical care, and research. Lancet Neurol. 2017;16(12):987–1048.
    1. Thelin EP, Nelson DW, Bellander BM. A review of the clinical utility of serum S100B protein levels in the assessment of traumatic brain injury. Acta Neurochir (Wien). 2017;159(2):209–225.
    1. Zetterberg H, Blennow K. Fluid biomarkers for mild traumatic brain injury and related conditions. Nat Rev Neurol. 2016;12(10):563–574.
    1. Yue JK, Yuh EL, Korley FK, et al. . Association between plasma GFAP concentrations and MRI abnormalities in patients with CT-negative traumatic brain injury in the TRACK-TBI cohort: A prospective multicentre study. Lancet Neurol. 2019;18(10):953–961.
    1. Richter S, Winzeck S, Kornaropoulos EN, et al. . Neuroanatomical substrates and symptoms associated with magnetic resonance imaging of patients with mild traumatic brain injury. JAMA Netw Open. 2021;4(3):e210994.
    1. Jolly AE, Bălăet M, Azor A, et al. . Detecting axonal injury in individual patients after traumatic brain injury. Brain. 2021;144(1):92–113.
    1. Ashton NJ, Janelidze S, Al Khleifat A, et al. . A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat Commun. 2021;12(1):3400.
    1. Rajan KB, Aggarwal NT, McAninch EA, et al. . Remote blood biomarkers of longitudinal cognitive outcomes in a population study. Ann Neurol. 2020;88(6):1065–1076.
    1. Wilson L, Stewart W, Dams-O’Connor K, et al. . The chronic and evolving neurological consequences of traumatic brain injury. Lancet Neurol. 2017;16(10):813–825.
    1. Needham EJ, Stoevesandt O, Thelin EP, et al. . Complex autoantibody responses occur following moderate to severe traumatic brain injury. J Immunol. 2021;207(1):90–100.
    1. Johnson VE, Stewart JE, Begbie FD, Trojanowski JQ, Smith DH, Stewart W. Inflammation and white matter degeneration persist for years after a single traumatic brain injury. Brain. 2013;136(Pt 1):28–42.
    1. Graham NSN, Zimmerman KA, Moro F, et al. . Axonal marker neurofilament light predicts long-term outcomes and progressive neurodegeneration after traumatic brain injury. Sci Transl Med. 2021;13(613):eabg9922.
    1. Shahim P, Politis A, van der Merwe A, et al. . Neurofilament light as a biomarker in traumatic brain injury. Neurology. 2020;95(6):e610––e622..
    1. Shahim P, Politis A, van der Merwe A, et al. . Time course and diagnostic utility of NfL, tau, GFAP, and UCH-L1 in subacute and chronic TBI. Neurology. 2020;95(6):e623–e636.
    1. Cole JH, Leech R, Sharp DJ. Alzheimer’s disease neuroimaging I. Prediction of brain age suggests accelerated atrophy after traumatic brain injury. Ann Neurol. 2015;77(4):571–581.
    1. Graham NS, Sharp DJ. Understanding neurodegeneration after traumatic brain injury: From mechanisms to clinical trials in dementia. J Neurol Neurosurg Psychiatry. 2019;90(11):1221–1233.
    1. Pereira JB, Janelidze S, Smith R, et al. . Plasma glial fibrillary acidic protein is an early marker of Aβ pathology in Alzheimer’s disease. Brain. 2021;144:3505–3516.
    1. Ledig C, Heckemann RA, Hammers A, et al. . Robust whole-brain segmentation: Application to traumatic brain injury. Med Image Anal. 2015;21(1):40–58.
    1. Taylor JR, Williams N, Cusack R, et al. . The Cambridge centre for ageing and neuroscience (Cam-CAN) data repository: Structural and functional MRI, MEG, and cognitive data from a cross-sectional adult lifespan sample. Neuroimage. 2017;144(Pt B):262–269.
    1. Shafto MA, Tyler LK, Dixon M, et al. . The Cambridge centre for ageing and Neuroscience (Cam-CAN) study protocol: A cross-sectional, lifespan, multidisciplinary examination of healthy cognitive ageing. BMC Neurol. 2014;14:204.
    1. Ashburner J, Friston KJ. Voxel-based morphometry–the methods. Neuroimage. 2000;11(6 Pt 1):805–821.
    1. Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage. 2007;38(1):95–113.
    1. Ashburner J, Ridgway GR. Symmetric diffeomorphic modeling of longitudinal structural MRI. Front Neurosci. 2012;6:197.
    1. Ashburner J, Friston KJ. Diffeomorphic registration using geodesic shooting and Gauss-Newton optimisation. Neuroimage. 2011;55(3):954–967.
    1. Cole JH, Jolly A, de Simoni S, et al. . Spatial patterns of progressive brain volume loss after moderate-severe traumatic brain injury. Brain. 2018;141(3):822–836.
    1. Graham NSN, Jolly A, Zimmerman K, et al. . Diffuse axonal injury predicts neurodegeneration after moderate-severe traumatic brain injury. Brain. 2020;143(12):3685–3698.
    1. Manjon JV, Coupé P, Concha L, Buades A, Collins DL, Robles M. Diffusion weighted image denoising using overcomplete local PCA. PLoS One. 2013;8(9):e73021.
    1. Veraart J, Novikov DS, Christiaens D, Ades-Aron B, Sijbers J, Fieremans E. Denoising of diffusion MRI using random matrix theory. Neuroimage. 2016;142:394–406.
    1. Andersson JL, Skare S, Ashburner J. How to correct susceptibility distortions in spin-echo echo-planar images: Application to diffusion tensor imaging. Neuroimage. 2003;20(2):870–888.
    1. Andersson JLR, Sotiropoulos SN. An integrated approach to correction for off-resonance effects and subject movement in diffusion MR imaging. Neuroimage. 2016;125:1063–1078.
    1. Jeurissen B, Tournier JD, Dhollander T, Connelly A, Sijbers J. Multi-tissue constrained spherical deconvolution for improved analysis of multi-shell diffusion MRI data. Neuroimage. 2014;103:411–426.
    1. Tustison NJ, Avants BB, Cook PA, et al. . N4ITK: Improved N3 bias correction. IEEE Trans Med Imaging. 2010;29(6):1310–1320.
    1. Wasserthal J, Neher P, Maier-Hein KH. TractSeg - Fast and accurate white matter tract segmentation. Neuroimage. 2018;183:239–253.
    1. Newcombe VF, Correia MM, Ledig C, et al. . Dynamic changes in white matter abnormalities correlate with late improvement and deterioration following TBI: A diffusion tensor imaging study. Neurorehabil Neural Repair. 2016;30(1):49–62.
    1. Castano-Leon AM, Cicuendez M, Navarro B, et al. . Longitudinal analysis of corpus callosum diffusion tensor imaging metrics and its association with neurological outcome. J Neurotrauma. 2019;36(19):2785–2802.
    1. Kenney K, Iacono D, Edlow BL, et al. . Dementia after moderate-severe traumatic brain injury: Coexistence of multiple proteinopathies. J Neuropathol Exp Neurol. 2018;77(1):50–63.
    1. Ramlackhansingh AF, Brooks DJ, Greenwood RJ, et al. . Inflammation after trauma: Microglial activation and traumatic brain injury. Ann Neurol. 2011;70(3):374–383.
    1. Hill CS, Coleman MP, Menon DK. Traumatic axonal injury: Mechanisms and translational opportunities. Trends Neurosci. 2016;39(5):311–324.
    1. Maxwell WL, MacKinnon MA, Smith DH, McIntosh TK, Graham DI. Thalamic nuclei after human blunt head injury. J Neuropathol Exp Neurol. 2006;65(5):478–488.
    1. Braeckman K, Descamps B, Pieters L, Vral A, Caeyenberghs K, Vanhove C. Dynamic changes in hippocampal diffusion and kurtosis metrics following experimental mTBI correlate with glial reactivity. Neuroimage Clin. 2019;21:101669.
    1. Yasmin A, Pitkanen A, Jokivarsi K, Poutiainen P, Grohn O, Immonen R. MRS reveals chronic inflammation in T2w MRI-negative perilesional cortex - A 6-months multimodal imaging follow-up study. Front Neurosci. 2019;13:863.
    1. Susarla BT, Villapol S, Yi JH, Geller HM, Symes AJ. Temporal patterns of cortical proliferation of glial cell populations after traumatic brain injury in mice. ASN Neuro. 2014;6(3):159–170.
    1. Onyszchuk G, LeVine SM, Brooks WM, Berman NE. Post-acute pathological changes in the thalamus and internal capsule in aged mice following controlled cortical impact injury: A magnetic resonance imaging, iron histochemical, and glial immunohistochemical study. Neurosci Lett. 2009;452(2):204–208.
    1. Brenner M, Messing A. Regulation of GFAP Expression. ASN Neuro. 2021;13.
    1. Takahata K, Kimura Y, Sahara N, et al. . PET-detectable tau pathology correlates with long-term neuropsychiatric outcomes in patients with traumatic brain injury. Brain. 2019;142(10):3265–3279.
    1. Hong YT, Veenith T, Dewar D, et al. . Amyloid imaging with carbon 11-labeled Pittsburgh compound B for traumatic brain injury. JAMA Neurol. 2014;71(1):23–31.
    1. Moscoso A, Grothe MJ, Ashton NJ, et al. . Longitudinal associations of blood phosphorylated Tau181 and neurofilament light chain with neurodegeneration in Alzheimer disease. JAMA Neurol. 2021;78(4):396–406.
    1. Simren J, Leuzy A, Karikari TK, et al. . The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer’s disease. Alzheimers Dement. 2021;17(7):1145–1156.
    1. Karikari TK, Pascoal TA, Ashton NJ, et al. . Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: A diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19(5):422–433.
    1. Chatterjee P, Pedrini S, Stoops E, et al. . Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease. Transl Psychiatry. 2021;11(1):27.
    1. Cicognola C, Janelidze S, Hertze J, et al. . Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. Alzheimers Res Ther. 2021;13(1):68.

Source: PubMed

3
Tilaa